LC Therapeutics, INC 简介

LC Therapeutics (M) Sdn. Bhd. (LCTISB) is a wholly-owned subsidiary of LC Therapeutics, Inc. (LCTI), which is an innovative medical device company offering various products to treat mitral valve regurgitation and atrial fibrillation. LCTI was founded in 2013, and it was incorporated in Delaware, USA.The core technologies are True Endoscopic Mitral Valve Surgery (first in the world) for the Mitral Regurgitation disease, and Quadripolar technology (first in the world) for the Atrial Fibrillation disease.LCTISB will offer state-of-the-art R&D center, high-volume manufacturing facility, skilled clinical specialists, and competent in-house customer service representative to serve all physicians, customers, distributors and sales representative around the world. LCTI’s innovative technologies will result in company becoming profitable by 2015, and employ a minimum of 796 employees in 2018 with a minimum of 597 employees in Malaysia.2.Company OverviewLC Therapeutics, Inc. (IMI) was founded in April, 2013 by Dr. James Longoria and Mr. Roy Chin, two individuals who have complementary expertise and experience in the cardiovascular industry. Dr. Longoria is a nationally recognized cardiothoracic surgeon, and Mr. Roy Chin is a serial entrepreneur in the medical device industry, particularly in the area of minimally invasive and endoscopic surgeries.The current standard of care in treatment of mitral valve regurgitation and atrial fibrillation is via open sternotomy surgery (open the sternum bone of patient), which is a very invasive surgery therefore traumatic to patients, therefore cardiologists are holding off these patients for later surgery when patients have become very sick. LCTI has developed technologies to be used via endoscopic approach (via small little ports or holes in between ribs), which is preferred by physicians and patients due to a more rapid return to normal activities by patients, and LCTI devices will be able to serve patients in the early stage of the disease to treat millions of patients who suffer from mitral valve regurgitation and atrial fibrillation. LCTI products and surgical techniques will become the new standard of care in the next few years.